Skip to main content
. 2016 Feb 3;2(1):13–16. doi: 10.1016/j.wjorl.2015.11.001

Table 2.

Injection sites and incidence of post-injection dizziness or vertigo.

Injection site (quadrant) Transient dizzy rate Post-injection vertigo rate
Q1 8/35 (22.9%) 0/35 (0%)
Q2 20/120 (16.7%) 0/120 (0%)
Q3 13/92 (14.1%) 3/92 (3.3%)
Q4 6/31 (19.4%) 2/31 (6.5%)

Q1, anterior-superior quadrant; Q2, anterior-inferior quadrant; Q3, posterior-inferior quadrant, and Q4, posterior-superior quadrant.